176 related articles for article (PubMed ID: 17724355)
1. Questionable conclusions about epoetin alfa.
Kruse MW; Lee JJ
Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
[No Abstract] [Full Text] [Related]
2. Erythropoietic agents for anemia of critical illness.
Shermock KM; Horn E; Rice TL
Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
Driver PS
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
5. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy.
Meadowcroft AM; Gilbert CJ; Maravich-May D; Hayward SL
Am J Health Syst Pharm; 1998 Sep; 55(18):1898-902. PubMed ID: 9784769
[TBL] [Abstract][Full Text] [Related]
6. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.
Ortega A; Dranitsaris G; Puodziunas AL
Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
Nakagawa T
Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
[No Abstract] [Full Text] [Related]
8. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy.
Wolchok JD; Klimek VM; Williams L; Chapman PB
Cytokines Cell Mol Ther; 1999 Dec; 5(4):205-6. PubMed ID: 10850383
[TBL] [Abstract][Full Text] [Related]
10. New pharmacoeconomic option in uremic anemia management.
Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
[No Abstract] [Full Text] [Related]
11. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
12. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
13. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic interchange of darbepoetin alfa for epoetin alfa in a multiinstitution health care system.
Adamson R; Lew I; Allen P; Misuro A; Malacrida P
Am J Health Syst Pharm; 2005 Nov; 62(22):2416-9. PubMed ID: 16278336
[No Abstract] [Full Text] [Related]
15. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of anemia in Patient Blood Management from an economic perspective].
Bisbe Vives E
Rev Esp Anestesiol Reanim; 2015 Jun; 62 Suppl 1():80-5. PubMed ID: 26320350
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin and blood management in pediatric spine surgery.
Roye DP
Orthopedics; 1999 Jan; 22(1 Suppl):s158-60. PubMed ID: 9927120
[No Abstract] [Full Text] [Related]
18. Is there a place for epoetin alfa in managing anemia during critical illness?
Givens M; Lapointe M
Clin Ther; 2004 Jun; 26(6):819-29. PubMed ID: 15262453
[TBL] [Abstract][Full Text] [Related]
19. Blood conservation in the critically ill.
Thomas J; Martinez A
Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S11-8. PubMed ID: 17687066
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
